EPPTB is a potent and selective antagonist of the trace amine-associated receptor 1 (TAAR1), primarily utilized in research and development within the fields of neuroscience and pharmacology. TAAR1 plays a key role in modulating monoamine neurotransmitter systems, including dopamine, norepinephrine, and serotonin. This compound serves as a valuable tool for investigating TAAR1's involvement in psychiatric and neurological disorders such as schizophrenia, depression, addiction, and locomotor activity regulation. Researchers use EPPTB in in vitro and in vivo experiments to elucidate signaling pathways, assess receptor function, and identify potential therapeutic targets for neuropsychiatric conditions. Its applications are confined to laboratory settings and it is not intended for clinical use.